期刊文献+

应用固体分散技术提高口服短效避孕药体外稳定性的研究

Research on Improving the Stability in Vitro of Oral Short-acting Contraceptive Tablets Prepared by Solid Dispersion Technique
原文传递
导出
摘要 目的:探讨应用固体分散技术制备复方孕二烯酮片和复方左炔诺孕酮片的体外稳定性。方法:以加速稳定性试验(0~3个月)为评价依据,有关物质、含量和溶出度为评价指标,将自制的复方片与相应的普通片作稳定性对比研究。结果:自制复方孕二烯酮片及复方左炔诺孕酮片在有关物质、含量和溶出度方面均明显优于普通片。结论:固体分散技术可用于改善和提高口服短效避孕药的体外稳定性。 Objective: To explore the stability of combined gestodene tablets and levonorgestrel tablets by solid dispersion technique. Methods: Based on the accelerated stability test (0-3 months), involving the evaluation of related substances, content and dissolution, the stability was compared between tablets of two formulations prepared by solid dispersion technique and the corresponding ordinary tablets. Result: The self- made combined gestodene tablets and levonorgestrel tablets were significantly better than the ordinary tablets in related substances, content and dissolution. Conclution: Solid dispersion technique can be used to improve the stability in vitro of oral short-acting contraceptives.
出处 《生殖与避孕》 CAS CSCD 2012年第8期540-545,共6页 Reproduction and Contraception
基金 上海市计划生育科学研究所青年科技创新基金项目 课题编号Q2011-8
关键词 固体分散技术 孕二烯酮(Ges) 左炔诺孕酮(LNG) 有关物质 含量 溶出度 solid dispersion technique gestodene(Ges) levonorgestrel(LNG) related substances content dissolution
  • 相关文献

参考文献7

二级参考文献43

  • 1Rolf H. Polymorphism in the Pharmaceutical Industry [M]. Weinheim: WlLEY-VCH Verlag GmbH & Co. KgaA Press, 2000:259-281. 被引量:1
  • 2Kerc J, Srcic S, Mohar M, et al. Some physicochemical properties of glassy felodipine [J]. Int J Pharm, 1991, 68: 25-33. 被引量:1
  • 3Johari GP, Ram S, Astl G .Characterizing amorphous and microcrystalline solids by calorimetry [J]. J Non-Cryst Solids, 1990, 116: 282-285. 被引量:1
  • 4Mishima O, Calvert LD, Whalley E. An apparently firstorder transition between two amorphous phases of ice induced by pressure [J]. Nature, 1985, 314: 76-78. 被引量:1
  • 5Chokshi R J, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons [J]. Drug Deliv, 2007, 14: 33-45. 被引量:1
  • 6Matsunaga N, Nakamura K, Yamamoto A, et al. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window [J]. Mol Cancer Ther, 2006, 5: 80-88. 被引量:1
  • 7Dharmendra S, William C. Drug polymorphism and dosage form design: a practical perspective [J]. Adv Drug Deliv Rev, 2004, 56: 335-347. 被引量:1
  • 8Albano AA, Phuapradit W, Sandhu HK, et al. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability: US, 6482847[P]. 2002-11-19. 被引量:1
  • 9Shikura T, Ishizawa T, Suemune K, et al. Amorphous substance of tricyclic triazolobenzazepine derivative: US, 7229985 [P]. 2007-06-12. 被引量:1
  • 10Chono S, Takeda E, Seki T, et al. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin [J]. Int J Pharm, 2008, 347: 71-78. 被引量:1

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部